10,000 patients to reveal how safe midline catheters really are
NCT ID NCT07677696
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study follows 10,000 adults receiving a midline catheter for intravenous therapy lasting 1 to 4 weeks as part of routine care. Researchers track complications like infection, blockage, or blood clots to see how well these devices perform in everyday hospital settings. The goal is to provide clear evidence on whether midline catheters are a safe and effective choice for short-term IV access.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- midline catheter
- What this could lead to
- If successful, this study could confirm that midline catheters are a safe and effective option for short-term intravenous therapy, potentially reducing complications from other vascular access devices.
- What could go wrong
- As an observational study, it cannot prove cause and effect. Results may be influenced by differences in patient care or data collection across hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 10,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients aged 18 years or older receiving a first-time midline catheter as part of their routine clinical care for intravenous therapy expected to last 1 to 4 weeks.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * First-time midline catheter placement per physician order * Not enrolled in another clinical study * Willing and able to provide informed consent and comply with follow-up (unless consent waived by local ethics committee) Exclusion Criteria: * Deemed unsuitable by investigator (e.g., poor compliance or inability to communicate clearly) * Refusal of informed consent by patient or family member
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Safety and effectiveness of midline catheters are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Zibo Central Hospital
RECRUITINGZibo, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.